Skip to main content
    Q

    Quest Diagnostics Incorporated (DGX)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $262.26
    +2.66 (+1.02%)

    Market Cap: $28.56B

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Quest Diagnostics Incorporated (DGX) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Quest Diagnostics (DGX) trades at 23.8x trailing earnings and 2.4x sales. Its P/E of 23.8x is above its 5-year median of 16.2x. Its forward P/E is 21.5x. The median P/E across 11 similar companies is 28.5x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 10.7% higher over the next year. Its free cash flow yield is 4.8%.

    MultipleValue
    P/E (trailing)23.8x
    Forward P/E21.5x
    Price to sales2.4x
    Price to book3.8x
    EV/EBITDA14.4x
    Price to FCF21.0x
    EV/FCF24.4x
    PEG1.7
    FCF yield4.8%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 44.2% above 16.5x, its P/S is 33.3% above 1.8x and its P/B is 46.2% above 2.6x.

    MultipleCurrent5-year median10-year median
    P/E23.8x16.2x16.5x
    P/S2.4x1.7x1.8x
    P/B3.8x2.6x2.6x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 10.7x in 2020 to 17.9x in 2016.

    Year endPriceP/EP/SP/B
    2025$173.5317.6x1.8x2.7x
    2024$150.8616.9x1.7x2.5x
    2023$137.8815.8x1.7x2.5x
    2022$156.4415.8x1.8x3.1x
    2021$173.0112.2x2.0x3.4x
    2020$119.1710.7x1.7x2.4x
    2019$106.7916.3x1.9x2.6x
    2018$83.2713.2x1.5x2.2x
    2017$98.4917.4x1.8x2.8x
    2016$91.9017.9x1.8x2.8x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About DGX

    What is DGX's forward P/E ratio?

    Quest Diagnostics has a forward P/E ratio of 21.5x.

    Is DGX stock overvalued?

    GNG's valuation label for DGX is Fairly valued. Its P/E of 23.8x compares with a median of 28.5x across 11 similar companies.

    What is DGX's price to sales ratio?

    Quest Diagnostics has a price to sales ratio of 2.4x.

    What is Quest Diagnostics's average P/E ratio over 5 years?

    Quest Diagnostics's median P/E over the last 5 years is 16.2x, from 60 month-end values through Oct 2026.

    What is DGX's PEG ratio?

    Quest Diagnostics has a PEG ratio of 1.7.